sutures newsletter


FDA Warns About Opioids, Diabetes Medications

Pharmacy Focus

The U.S. Food and Drug Administration has issued warnings about safety issues with the entire class of opioid pain medicines and with Type 2 diabetes medicines containing saxagliptin and alogliptin.

Mark Your Calendar

Surgery Grand Rounds

Click the "read more" to see information about upcoming Surgery Grand Rounds.

Grand Rounds

Click here to view a schedule of all upcoming grand rounds.

Education Schedule

Click the PDF link below to see the Department of Surgery's education schedule.

Education Schedule - April 2016 (PDF)  

Education Schedule - May 2016 (PDF)  

Surgery Scheduling

Click the "read more" for hours and contact information for surgery scheduling.

Share Your News

Know an interesting colleague we should profile? A story we should tell? Submit your ideas, meetings and events for consideration.

Click here to submit your news to Sutures

Cedars-Sinai Helps Test Therapy for Sleep Apnea

Sleep apnea is a common chronic condition that often goes undiagnosed because people don't know they have the problem. Sleep apnea can be debilitating and life-threatening because not enough air reaches the lungs during sleep.

The Cedars-Sinai Sleep Apnea Treatment Center is taking part in a clinical trial to test a potential therapy for the most common form of the condition.

Management of sleep apnea can vary from lifestyle changes such as weight management and smoking cessation to using breathing devices such as continuous positive airway (CPAP) or having airway surgery.

There are several types of sleep apnea, but the most common is obstructive sleep apnea (OSA). In OSA the airway is collapsed or blocked during sleep, preventing air from getting to the lungs. The most noticeable sign is very loud snoring.

If left untreated, OSA can result in the patient developing depression, hypertension, heart failure, headaches and stroke, among other symptoms of chronic sleep deprivation. CPAP is usually the best treatment for OSA. Multiple studies have shown, however, that more than 45 percent of people who own CPAP machines do not comply and don't use them. So these patients' symptoms continue or get worse.

The Sleep Apnea Treatment Center, part of the Cedars-Sinai Sinus Center, is participating in a multicenter clinical trial of the ImThera Medical Targeted Hypoglossal Neurostimulator to evaluate the safety and efficacy of implantable therapy in patients who have moderate to severe obstructive sleep apnea and who cannot use CPAP therapy. This sleep apnea implant stimulates the hypoglossal nerve and the tongue muscles it innervates. The technology is designed to increase the resting tone of these muscles and keeps the tongue out of the airway, resulting in unobstructed air flow to the lungs and reducing or eliminating sleep apnea.

On March 15, 2016, the first implantable device was surgically placed by Martin L. Hopp, MD, PhD, Daryoush Saadat, MD, David M. Alessi, MD, Robert O. Ruder, MD, and Raj Terkonda, MD. A sleeve was placed around the hypoglossal nerve of a 69-year-old male patient who could not tolerate the CPAP machine.

The surgery was about one hour. Intraoperatively, the patient did very well, and postoperative recovery was without any complications. The device is activated by the patient through a handheld remote control to start the therapy at bedtime and turn off therapy in the morning.

Updates as to how the clinical study is progressing will be made available.